| Ticker |
SANA
|
| CIK | 0001770121 |
| SIC | 2836 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Biological Products, Except Diagnostic Substances |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Sana Biotechnology, Inc. (SANA) Secures an Overweight Rating from Morgan StanleySana Biotechnology, Inc. (NASDAQ:SANA) is among the fundamentally strong penny stocks to invest in. Morgan Stanley has assumed coverage on Sana Biotechnology, Inc. (NASDAQ:SANA) with an Overweight rating and a price target of $12.00. This optimism is totally in line with market sentiments that acknowledge the platform’s potential to develop tailored therapies driven by engineered […] Top Penny Stocks To Watch In July 2025In the last week, the market has been flat, but it is up 12% over the past year, with earnings expected to grow by 15% per annum over the next few years. Investing in penny stocks—though often seen as a niche area—can still offer growth opportunities, particularly when these stocks are supported by strong financial health. As we explore several penny stocks today, we'll focus on those that combine balance sheet strength with long-term potential. Sana Reports Promising Diabetes Cell Therapy Data at ADA MeetingSana Biotechnology, Inc. (NASDAQ:SANA) ranks among the best CRISPR stocks to buy. On June 24, Citizens JMP reaffirmed its $5 price target and Market Outperform rating for Sana Biotechnology, Inc. (NASDAQ:SANA) in light of new clinical data from its diabetes therapy program. The biotechnology company attended the American Diabetes Association meeting and presented new results […] Sana Biotechnology (SANA) Stock Surges on Positive Type 1 Diabetes Treatment ResultsSana Biotechnology, Inc. (NASDAQ:SANA) is one of the 10 best healthcare penny stocks to buy according to analysts. The company’s stock surged 12.1% on June 23 after it announced positive six-month follow-up results from an investigator-sponsored, first-in-human study of its type 1 diabetes treatment. The therapy in focus is UP421, which consists of cadaver-sourced pancreatic […] BofA Remains Bullish on Sana Biotechnology (SANA)Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On May 14, Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Sana Biotechnology, Inc. (NASDAQ:SANA) and set a price target of $6.00. The rating update came after the company announced on May 12 […] |
